I’m still very interested in where Sarepta are going to spend that 500 million. Conference call tonight/tomorrow our time.
Professor Voit being P.I for our upcoming trial & also having 25% ownership in the microdystophin patent that Sarepta use seems rather peculiar to me?
There is still a lot of un answered questions. I wonder what ANP will pull from up its sleeve to make sure the capital raising is fully taken up by retail?
$15m cap raise Fresh Equities at 24c, page-350
-
- There are more pages in this discussion • 506 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
